{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:43Z","timestamp":1787166583311,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Objective: To identify pretreatment laboratory parameters associated with treatment response and to describe the relationship between treatment response and liver decompensation in patients with primary biliary cholangitis treated with ursodeoxycholic acid. Methods: We defined treatment response as both ALP \u2264 1.67 \u00d7 ULN and total bilirubin \u2264 2 \u00d7 ULN. Multiple logistic regression analyses were performed to adjust for confounding effects of sociodemographic variables. Results: Pretreatment total bilirubin ((TB); OR = 0.3388, 95%CI = 0.1671\u20130.6077), ALT (OR = 0.5306, 95%CI = 0.3830\u20130.7080), AST (OR = 0.4065, 95%CI = 0.2690\u20130.5834), ALP (OR = 0.3440, 95%CI = 0.2356\u20130.4723), total cholesterol ((TC); OR = 0.7730, 95%CI = 0.6242\u20130.9271), APRI (OR = 0.3375, 95%CI = 0.1833\u20130.5774), as well as pretreatment albumin (OR = 1.1612, 95%CI = 1.0706\u20131.2688) and ALT\/ALP (OR = 2.4596, 95%CI = 1.2095\u20135.5472) were associated with treatment response after six months of treatment. Pretreatment TB (OR = 0.2777, 95%CI = 0.1288\u20130.5228), ALT (OR = 0.5968, 95%CI = 0.4354\u20130.7963), AST (OR = 0.4161, 95%CI = 0.2736\u20130.6076), ALP (OR = 0.4676, 95%CI = 0.3487\u20130.6048), APRI (OR = 0.2838, 95%CI = 0.1433\u20130.5141), as well as pretreatment albumin (OR = 1.2359, 95%CI = 1.1257\u20131.3714) and platelet count (OR = 1.0056, 95%CI = 1.0011\u20131.0103) were associated with treatment response after 12 months of treatment. Treatment response after 6 months of UDCA therapy is significantly associated with treatment response after 12 months of UDCA therapy (OR = 25.2976, 95% CI = 10.5881\u201368.4917). Treatment responses after 6 and 12 months of UDCA therapy decrease the risk of an episode of liver decompensation in PBC patients (OR = 12.1156, 95%CI = 3.7192\u201354.4826 and OR = 21.6000, 95%CI = 6.6319\u201397.3840, respectively). Conclusions: There are several pretreatment laboratory parameters associated with treatment response in patients with primary biliary cholangitis. Treatment response after six months is significantly associated with treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy. Treatment responses after 6 and 12 months of UDCA decrease the risk of an episode of liver decompensation.<\/jats:p>","DOI":"10.3390\/jpm11060495","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T15:58:44Z","timestamp":1622563124000},"page":"495","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-2217","authenticated-orcid":false,"given":"Jakub","family":"Gazda","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Drazilova","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia"},{"name":"Internal Medicine Department, Hospital Poprad, a.s., 058 01 Poprad, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-3968","authenticated-orcid":false,"given":"Martin","family":"Janicko","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Grgurevic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia"},{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tajana","family":"Filipec Kanizaj","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia"},{"name":"Department of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-0073","authenticated-orcid":false,"given":"Tomas","family":"Koller","sequence":"additional","affiliation":[{"name":"5th Department of Internal Medicine, Subdivision of Gastroenterology and Hepatology, Comenius University Faculty of Medicine, University Hospital Bratislava, Ruzinovska 6, 826 06 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrica","family":"Bodorovska","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterological Internal Medicine, Comenius University in Bratislava and University Hospital Martin, Kollarova 2, 036 59 Martin, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonci","family":"Bozin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-1013","authenticated-orcid":false,"given":"Maja","family":"Mijic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Rob","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Mikolasevic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, 10000 Zagreb, Croatia"},{"name":"Department of Gastroenterology, School of Medicine, University of Rijeka, Brace Branchetta 20\/1, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-1869","authenticated-orcid":false,"given":"Anita","family":"Madir","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Clinical Nutrition, School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Kucinsky","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jarcuska","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00038-020-01391-6","article-title":"Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia","volume":"65","author":"Drazilova","year":"2020","journal-title":"Int. J. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3325\/cmj.2019.60.494","article-title":"Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: A retrospective study","volume":"60","author":"Madir","year":"2019","journal-title":"Croat. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clinre.2015.10.006","article-title":"Assessment of health related quality of life in polish patients with primary biliary cirrhosis","volume":"40","author":"Wunsch","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis","volume":"35","author":"Quarneti","year":"2015","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: Development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.5009\/gnl18271","article-title":"Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio","volume":"12","author":"Yoo","year":"2018","journal-title":"Gut Liver"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cgh.2019.12.008","article-title":"Beyond Biochemical Responses, Use of Histologic Staging to Predict Outcomes of Patients With Primary Biliary Cholangitis","volume":"18","author":"Gulamhusein","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.21151","article-title":"Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC","volume":"43","author":"Corpechot","year":"2006","journal-title":"Hepatology"},{"key":"ref_24","first-page":"e404","article-title":"Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test","volume":"70","author":"Perez","year":"2019","journal-title":"Red"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis","volume":"55","author":"Osman","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.ejim.2012.09.004","article-title":"Primary biliary cirrhosis in Southern Israel: A 20 year follow up study","volume":"23","author":"Delgado","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/apt.13244","article-title":"Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis","volume":"42","author":"Guo","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/495\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:47Z","timestamp":1760162987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jpm11060495"],"URL":"https:\/\/doi.org\/10.3390\/jpm11060495","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}